We thus cannot adequately assess the contribution of genetic factors in this population, although the prevalence of 192 Gln/Arg and 55 Leu/Met PON‐1 polymorphisms reportedly do not appear to differ between patients with chronic renal failure and control subjects.34 Despite these limitations, to our knowledge, this study represents the first examination of the contribution of PON‐1 activity to long‐term adverse cardiac events in a large cohort of well‐characterized subjects with moderate CKD. The gene discussed is PON1; the disease is chronic kidney disease.